Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

α-Synuclein overexpression increases the tropism of pre-formed fibrils and MSA-patient derived seeds towards oligodendroglia.

Acta neuropathologica communications·2026
Same author

Long-Term Outcomes From a Decade of Donation After Circulatory Death Heart Transplantation in Australia.

JACC. Heart failure·2026
Same author

Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.

Science advances·2026
Same author

Creutzfeldt-Jakob disease is an Alzheimer's disease-related dementia.

Trends in molecular medicine·2026
Same author

Single-nucleus brain transcriptomics reveals microglia dysfunction in multiple system atrophy.

Nature communications·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Suelyn Koerich1, Santiago Ramirez1, Natalia Astudillo1

  • 1The University of Texas Health Science Center at Houston, Houston, TX, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括

血交换 (PE) 在晚期阿尔茨海默病 (AD) 的小鼠中减少了粉样蛋白斑块和大脑炎症. 这表明PE可能有助于从大脑中清除粉样β (Aβ),这需要进一步研究AD治疗.

科学领域:

  • 神经科学是一个神经科学.
  • 免疫学 免疫学 免疫学
  • 生物化学 生物化学

背景情况:

  • 阿尔茨海默病 (AD) 是痴呆的主要原因,其特点是粉样质斑块,神经纤维状结和神经炎症.
  • 目前针对粉样质斑块的AD疗法在符合条件和风险-益处概况方面存在局限性.
  • 边缘策略正在被探索,因为它们有可能影响大脑Aβ和病理,以及神经炎症.

研究的目的:

  • 在AD小鼠模型中研究血交换 (PE) 降低粉样蛋白病理和神经炎症的疗效.
  • 评估PE对粉样β (Aβ) 沉积和大脑和血中的炎症标记物的影响.

主要方法:

  • 从11个月大开始,每月一次PE程序被用于APP/PS1小鼠.
  • 组织学分析量化了粉样蛋白沉积物 (Thioflavin-S,4G8) 和神经炎症标志物 (Iba-1,GFAP).
  • ELISA和Luminex测定测量了Aβ水平和细胞因子度在大脑同质物和血中.

主要成果:

  • PE显著减少了治疗小鼠皮质中的粉样蛋白斑块数量和面积.
  • 在脑中PE降低了微质细胞 (Iba-1) 和天体细胞 (GFAP) 的激活.
  • 生物化学分析显示,PE治疗小鼠大脑中的不溶性Aβ1-40和Aβ1-42水平较低,以及调制的炎症性细胞因子配置.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

结论:

  • 血交换证明了在高级AD小鼠模型中降低大脑粉样蛋白负担和调节神经炎症的潜力.
  • 在PE后血Aβ水平增加表明Aβ从大脑清除到外围的机制.
  • 需要进一步的研究,以充分阐明Aβ清除的机制和PE的抗炎作用.